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Mitochondria play essential role in eukaryotic cells including in the oxidative phosphorylation and generation of ad-
enosine triphosphate via the electron-transport chain. Therefore, defects in mitochondrial DNA (mtDNA) can result 
in mitochondrial dysfunction which leads to various mitochondrial disorders that may present with various neurologic 
and non-neurologic manifestations. Mutations in the nuclear gene polymerase gamma (POLG) are associated with 
mtDNA depletions, and Alpers-Huttenlocher syndrome is one of the most severe manifestations of POLG mutation 
characterized by the clinical triad of intractable seizures, psychomotor regression, and liver failure. The hepatic mani-
festation usually occurs late in the disease’s course, but in some references, hepatitis was reportedly the first 
manifestation. Liver transplantation was considered contraindicated in Alpers-Huttenlocher syndrome due to its poor 
prognosis. We acknowledged a patient with the first manifestation of the disease being hepatic failure who eventually 
underwent liver transplantation, and whose neurological outcome improved after cocktail therapy.
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INTRODUCTION
Alpers-Huttenlocher syndrome (AHS), which first 
received attention from Alpers in 1931 [1] and was 
further described with its hepatic manifestation by 
Huttenlocher et al. [2] and Harding [3], is a rare mi-
tochondrial disease characterized by its classic triad 
of refractory seizures, psychomotor regression, and 
hepatopathy [3]. In 1999, Naviaux et al. [4] estab-
lished the biochemical and enzymatic relevance of 
polymerase gamma (POLG) in AHS with their de-
scription of mitochondrial DNA depletion and re-
duced POLG activity. In most cases, the first manifes-
tation of AHS is a neurodevelopmental delay or in-
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Fig. 1. Liver histopathology (H&E, ×100). The histopathology 
confirmed marked fatty change, cholestasis, ballooning 
degeneration and marked ductular proliferation, favoring 
metabolic disease.
Fig. 2. Brain magnetic resonance imaging (MRI). MRI showed multifocal diffusion restriction area in left insula, deep gray matter 
and bilateral peri-rolandic area.
tractable seizures, but it has been reported that in 
some rare cases its first manifestation is hepatic [5]. 
Hepatic failure is most commonly presented in the 
preterminal stage regardless of valproate exposure, 
and many patients die due to either hepatic failure or 
neurological deterioration [5,6]. 
Our team investigated a 10-month-old patient 
with AHS whose first manifestation was hepatic fail-
ure he received liver transplantation and later devel-
oped epilepsy and psychomotor regression. His prog-
nosis was sufficiently good to be discharged from 
hospital with neurodevelopmental improvement.
CASE REPORT
A 10-month-old male patient was admitted for 
persistent hepatitis and jaundice. He did not have any 
perinatal, familial, or past history except that he had 
received treatment for bronchitis in another hospital 
two weeks prior to admission. His aspartate amino-
transferase (AST) and alanine aminotransferase 
(ALT) were elevated upon his admission for bronchi-
tis, and reactive hepatitis was suspected because of 
his intact liver function and clinical history. However, 
he eventually developed impending hepatic failure, 
and was referred to the hepatology department. The 
initial laboratory finding suggested acute liver failure 
with AST and ALT levels of 194 IU/L and 69 IU/L, total 
and direct bilirubin of 7.4 mg/dL and 6.3 mg/dL, am-
monia of 57 μg/dL, and gamma-glutamyl trans-
peptidase of 101 IU/L, respectively. His initial blood 
gas analysis test, with normal pH of 7.40 and bicar-
bonate of 25.8 mmol/L, was not suggestive of definite 
metabolic acidosis, although the lacate level was 
slightly elevated to 2.4 mmol/L. Numerous evalua-
tions such as viral, autoimmune, endocrinologic, and 
genetic studies for ATP7B and ABCB11 were per-
formed that all turned out normal, and there were no 
remarkable findings in his imaging study. The lac-
tate-to-pyruvate ratio was 82.5, and plasma amino 
acid assay suggested the possibility of lactic acidosis. 
Therefore, the whole exome sequencing (WES) anal-
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Table 1. Heterozygous Mutation of Polymerase Gamma (POLG) Gene
Gene HGVS Patient Parent A Parent B
POLG NP_002684.1:p.Arg807His O, hetero X O, hetero
POLG NP_002684.1:p.Arg627Trp O, hetero O, hetero X
Compound heterozygous mutation of POLG gene (p.Arg807His and p.Arg627Trp) was found.
ysis was sent out for further evaluation. Meanwhile, 
his mental status became drowsy with hyper-
ammonemia, and he received a living donor liver 
transplantation at admission day 24. The pathologist 
confirmed cirrhosis with marked fatty change, cho-
lestasis, ballooning degeneration and marked ductu-
lar proliferation, favoring metabolic disease (Fig. 1). 
The liver transplantation was successful, and he was 
discharged home with normal neurological function. 
One month later, he was readmitted to the neurology 
department for eye blinking and myoclonus on the 
right side of his face. Electroencephalogram (EEG) 
was performed, which determined left periodic later-
alized epileptiform discharges, and brain magnetic 
resonance imaging (MRI) showed multifocal dif-
fusion restriction areas in the left insula, deep gray 
matter and bilateral perirolandic area, suggesting 
metabolic disorder (Fig. 2). A combination therapy of 
six antiepileptic drugs did not improve his con-
tinuous myoclonic seizures, and other symptoms 
such as psychomotor regression, nystagmus, swal-
lowing difficulty and frequent central apnea sub-
sequently occurred. WES revealed the known com-
pound heterozygous mutation of the POLG gene 
(p.Arg807His and p.Arg627Trp), confirming AHS 
(Table 1). The EEG pattern evolved to a generalized 
slow spike and waves with generalized paroxysmal 
fast activities in the left hemisphere, and follow-up 
MRI showed diffuse cerebral atrophy, especially on 
the left posterior quadrant. Valproate was dis-
continued immediately, and a mitochondrial cocktail 
therapy comprised of thiamine, coenzyme Q10 
(CoQ10), and L-carnitine was started. After four 
months of this cocktail therapy, the number of apnea 
events had reduced and nystagmus and motor func-
tion had slightly improved. The feeding problem was 
resolved after the gastrostomy, and he could tolerate 
enteral feeding without reflux. Recently, he was able 
to intake some feeding per oral. He was discharged 
home after one year of hospitalization.
DISCUSSION
AHS is a mitochondrial disease caused by autoso-
mal recessive POLG mutation [5]. POLG is the DNA 
polymerase in mitochondria that is responsible for 
mitochondrial DNA replication and repair in the mi-
tochondria of eukaryotic cells [7]. Ultimately, a sig-
nificant amount of mitochondrial DNA depletion is 
noted when mutation occurs in POLG which leads to 
dysfunction in multiple organs such as the brain and 
liver [7]. The first manifestation usually starts with 
seizures or psychomotor regression. Liver involve-
ment was rarely reported as the first manifestation, 
and it is mostly associated with preterminal disease 
stage [5]. There is no available treatment with which 
the clinical course of the disease can be modified, 
and patients with this disease die within four years 
of the onset of features [5]. Therefore, liver trans-
plantation is said to be contraindicated in the disease 
due to the poor prognosis even after the successful 
transplantation [5,6]. The treatment of this disease 
is focused on symptomatic treatment for the control 
of seizures, ventilation disorders, or nutritional is-
sues [5]. Valproate is usually contraindicated in AHS 
since it can accelerate the dysfunction of mitochon-
dria, leading to liver failure [6]. In our case, although 
the patient had already undergone liver trans-
plantation, we decided to discontinue valproate 
since it did not seem to be essential for controlling 
his seizures. Cocktail therapy including vitamins and 
CoQ10 can be considered as a treatment option in 
mitochondrial disease by enhancing the mitochon-
drial function [8]. 
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In the literature review, this was the first report of 
AHS presenting its first manifestation as liver failure 
[5]. The patient’s neurological function was normal 
even after liver transplantation, and he was dis-
charged to home and began to develop epilepsia parti-
alis continua one month after liver transplantation. A 
cocktail therapy for mitochondrial disease was start-
ed after the diagnosis of POLG mutation, and it 
seemed to stabilize our patient’s organ function even 
though we could not stop his partial seizures. We 
could presume that his organic dysfunction and clin-
ical symptoms became more severe than the degree 
of his DNA depletion, which resulted in the positive 
prognosis of his clinical symptoms with CoQ10 and 
vitamin support.
AHS is one of the most severe phenotypes of POLG 
mutation and is a fatal disease for which there is no 
available treatment that modifies its clinical course. 
However, we want to make the point that liver trans-
plantation can be considered as a treatment option if 
the disease’s course is stable, especially when pre-
senting at a late age. Moreover, in a patient with liver 
failure of unknown etiology, investigation including 
genetic study should always be considered when 
there are signs of metabolic disorders.
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